We're booking big profits in 2 outperformers in Thursday's terrible market

Jim Cramer's Charitable Trust plans to sell 50 Cardinal Health shares at roughly $273 and 10 Eli Lilly shares at roughly $1,420, lowering each position's portfolio weighting from 3% to 2.75% and 2.6%, respectively. The Trust cites rallies of more than 20% in both stocks since late September and says it is trimming into strength while retaining them for diversification. Cardinal Health recently beat earnings expectations and raised its full-year outlook; Eli Lilly reported a strong beat and raise last week.

Analysis

The trims are portfolio housekeeping, not a fundamental signal: one manager’s modest sales do not establish institutional distribution or change either company’s earnings path. The more useful read-through is that healthcare is being used as a source of relative resilience during a sharp tech/data-center drawdown; if that risk-off rotation persists, flows could support the group temporarily, but it does not remove company-specific valuation or execution risk.

For CAH, the earnings beat and higher outlook warrant checking whether improvement is broad-based across volumes, mix, and cash conversion rather than relying on one quarter. McKesson and Cencora are relevant read-throughs: evidence of stronger distributor economics should be tested against their results, not assumed from CAH alone. For LLY, the key medium-term test is whether demand translates into scalable supply and durable earnings expectations; Novo Nordisk is the closest competitive read-through. The article supplies no valuation, consensus, or detailed operating metrics, so it cannot establish that either stock is overvalued after its rally.

Days: the trim itself is unlikely to be a material catalyst. Over 1–3 months, earnings detail and guidance follow-through matter more. Over 6–18 months, CAH’s operating execution and LLY’s ability to convert product demand into supply and earnings will determine whether recent relative strength is durable. Contrarian point: taking profits after a run is not evidence the upside is exhausted; equally, defensive rotation can reverse quickly if tech leadership returns.

Key Decisions for Investors

• No trade on the Trust’s sales alone; avoid treating a small portfolio trim as a bearish change in fundamentals.
• For CAH, stay constructive only if subsequent results support the raised outlook through operating performance and cash conversion. Reassess if guidance is cut or comparable distributor results weaken; monitor MCK and COR as sector checks.
• For LLY, do not chase the rally solely on defensive-sector flows. Track supply, realized demand, and earnings guidance alongside Novo Nordisk; weaker execution or a reversal in estimates would falsify the continuation thesis.
• Near term, retain healthcare exposure as a possible diversifier rather than a stand-alone rotation bet. Revisit sizing if technology leadership resumes and healthcare relative strength fades.